Rejuve.Bio

What Rejuve.Bio does

Rejuve Biotech (operating as Rejuve.Bio) is a privately held AI-driven biomedical research company founded in 2022 and headquartered in Orange, California. The company's core product is Mozi, an AI co-scientist platform that unifies genetic, clinical, and preclinical datasets into a structured knowledge graph, generates testable hypotheses about biological pathways and candidate treatments using neural-symbolic AI, and validates those hypotheses against biological systems (Methuselah Fly outcomes) and human health data from the affiliated Rejuve Network. The platform is positioned to accelerate drug discovery for aging and age-related diseases — including Alzheimer's and cardiovascular decline — by addressing three structural problems in the field: high development cost (billions of dollars), long timelines (years of trial and error), and siloed datasets that do not connect across species, labs, and populations.

The primary stated customer segment is pharmaceutical companies and biotech research organizations seeking AI-augmented drug discovery capabilities. The company operates an invite-only beta testing program accessed via direct email ([email protected]), has no publicly disclosed pricing, and appears to be in early commercialization. A related consumer-facing initiative, Rejuve.AI, was launched in June 2025 as a token-incentivized app intended to collect holistic genomic, clinical, lifestyle, and psychological health data from individuals, feeding a data flywheel that supports the research platform. Rejuve Biotech is venture-backed, having raised $288,551 in a December 2024 funding round (investors undisclosed), has between 1 and 10 employees, and joined the Lifespan Alliance in August 2024 as part of a broader longevity-research coalition.

Name

Rejuve.Bio

Legal name

Rejuve Biotech

Website

https://rejuve.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Rejuve Biotech builds Mozi, an AI co-scientist platform using neural-symbolic AI and a biomedical knowledge graph to accelerate drug discovery for aging and age-related diseases, targeting pharmaceutical and biotech research organizations through an invite-only beta program.

Ownership category

akta.pro rank

Product category

AI-driven drug discovery platform

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• AI drug discovery
• Longevity therapeutics
• Biomedical AI platform
• Translational medicine research
• Knowledge graph analytics

Headquarters

HQ city

Orange

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Rejuve.Bio builds and operates Mozi, an AI-driven biomedical research platform that unifies genetic, clinical, and preclinical datasets into a knowledge graph, generates testable therapeutic hypotheses using neural-symbolic AI, and validates them against Methuselah Fly outcomes and human health data from the Rejuve Network. The company targets pharmaceutical and biotech researchers working on aging and age-related diseases, and supplements this enterprise platform with the consumer-facing Rejuve.AI app that collects token-incentivized holistic health data.

Product overview

Rejuve.Bio is building an AI-driven research platform focused on translational medicine and therapeutic discovery for aging and age-related diseases. The core offering is Mozi, an AI co-scientist platform that unifies datasets, generates hypotheses, and validates findings. Additionally, the company operates Rejuve.AI (referenced in affiliated news), a consumer-facing longevity research app that collects health data through token-based incentives. The two products serve different segments: Mozi for biomedical researchers and drug discovery, and Rejuve.AI for consumer health data contribution.

Differentiator

Problem solved

Functional benefit

Brands

• Mozi: AI co-scientist platform developed by Rejuve Biotech that builds structured knowledge, generates testable hypotheses, and validates them with living systems.

Products and services

• Mozi AI co-scientist platform that builds structured knowledge, generates testable hypotheses, and validates them with living systems to discover interventions for aging and age-related diseases; targeted at pharmaceutical and biotech research organizations.
• Rejuve.AI App Consumer-facing longevity research application that uses token-based incentives to gather holistic health data (genomic, clinical, lifestyle, psychological) from users to support AI-driven longevity research.

Quantifiable outcome

• Aims to build the world's largest corpus of holistic health data across people's lifespans

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

One partnership is on record.

• Lifespan AlliancecoreStrategic or Co-development Partner · 15 August 2024Rejuve Biotech joined the Lifespan Alliance, a coalition focused on longevity research and interventions. The Lifespan Alliance is associated with Lifespan.io, an organization dedicated to accelerating longevity science. This partnership positions Rejuve Biotech within a broader ecosystem of longevity-focused entities.

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's AlphaFold and related models. A much larger and better-capitalized incumbent operating in the same AI-for-drug-discovery space.
• Ginkgo Bioworks: Synthetic biology platform company combining automated labs with AI to engineer organisms. Comparable as an AI + biology platform targeting R&D, though with a broader industrial biotech remit.

Emerging players

• Owkin: AI biotech combining federated learning on patient data with drug discovery and development. Adjacent overlap on biomedical data integration and AI-driven target identification.
• Altos Labs: Well-capitalized longevity biotechnology company focused on cellular rejuvenation programming. Direct peer in the aging/age-related disease therapeutic mission, with substantially more capital and scientific scale.

Direct peers

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Direct competitor to Mozi in AI-enabled pharma R&D, though operating at significantly larger scale and capital base.
• Recursion Pharmaceuticals: AI-enabled drug discovery platform combining automated wet-lab experiments with machine learning to map biology and identify novel therapeutics. Closely comparable in mission and architecture, with established pharma partnerships (e.g., Roche, Bayer).
• Schrödinger: Computational chemistry and molecular simulation platform used for drug discovery across pharma and biotech. Direct peer in AI-driven molecular design and predictive modeling, serving overlapping customer base.
• BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Closely analogous architecture to Mozi's knowledge-graph approach.
• Exscientia: AI-driven precision medicine company focused on end-to-end drug discovery using AI-designed molecules. Comparable in applying AI to compress drug discovery timelines for pharma partners.
• Insilico Medicine: AI-driven drug discovery company with end-to-end platforms for target identification, generative chemistry, and clinical prediction. Closely comparable to Mozi in applying AI to aging and age-related disease pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/Rejuve_Bio
• YouTubeyoutube.com/@RejuveBio
• LinkedInlinkedin.com/company/rejuve-bio
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rejuve.Bio